A Double Blinded Study of the Effect on Post-prandial Glycemia, Safety, and Tolerability of VIAject vs. Lispro Insulin during Subcutaneous Insulin Pump Therapy

Trial Profile

A Double Blinded Study of the Effect on Post-prandial Glycemia, Safety, and Tolerability of VIAject vs. Lispro Insulin during Subcutaneous Insulin Pump Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Aug 2015

At a glance

  • Drugs Insulin (Primary) ; Insulin lispro (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacokinetics; Registrational
  • Sponsors Biodel
  • Most Recent Events

    • 01 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Apr 2010 Planned number of patients (24) and actual initiation date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 28 Apr 2010 New source identified and integrated (ClinicalTrials.gov record no. NCT01110746).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top